Drugs active against hepatitis viruses;Medicaments actifs contre les virus des hepatites

Revue du Praticien

Volumn 47, Issue 6, 1997, Pages 640-645

  Goudeau, Alain ^a  

^a CHU BRETONNEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; BETA INTERFERON; DIDANOSINE; FAMCICLOVIR; FIALURIDINE; FOSCARNET; GAMMA INTERFERON; LAVIMUDINE; RIBAVIRIN; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTIVIRUS AGENT; INTERFERON; NUCLEOSIDE;

ARTICLE; DRUG ACTIVITY; DRUG EFFICACY; HEPATITIS; HEPATITIS VIRUS; HUMAN; DELTA AGENT HEPATITIS; DRUG EFFECT; HEPATITIS B; HEPATITIS C; REVIEW;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS C; HEPATITIS D; HEPATITIS VIRUSES; HUMANS; INTERFERONS; NUCLEOSIDES;

EID: 0030940705     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Marcellin P. Traitement des hépatites chroniques virales. Med Mal Infect 1996; 26: 465-8.
2. Fattovich G, Giustina G, Favarato S, Ruol A and the investigators of the Italian Association for the Study of the Liver. A survey of the adverse events in 11 241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 1996; 24: 38-47.
3. Lok ASF. Treatment of chronic hepatitis B.J Viral Hepatitis 1994; 1: 105-24.
4. Bozkaya H, Ayola B, Lok ASF. High rate of mutations in the hepatitis core gene during the immune clearance phase of chronic hepatites B virus infection. Hepatology 1996; 24: 32-7.
5. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7.
6. Torre D, Tambini R. Interferon-α therapy for chronic hepatitis B in children : a meta-analysis. Clin Infect Dis 1996; 23: 131-7.
7. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alpha: an economic appraisal. Hepatology 1995; 22: 1863-73.
8. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effect of dose and duration. Hepatology 1996; 24: 778-89.
9. Craxi A, Almasio P, Schalm S. Evaluation of efficacy of antiviral therapy for chronic hepatitis C: a EUROHEP consensus report on response criteria. J Viral Hepatitis 1996; 3: 273-6.
10. Marcellin P, Pouteau M, Martinot M et al. Gastroenterol Clin Biol 1995; 19: 991-1000.
11. Lin C, Liddle K, Byth K, Farrell GC Virus and hostifactors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J Viral Hepatitis 1996; 3: 85-96.
12. Brechot C. Hepatitis C virus: molecular biology and genetic variability. In : Hepatitis C virus : genetic heterogeneity and viral load, édit Groupe français d'études molé culaires des hépatites (GEMHEP) (Paris) : John Libbey Eurotext 1997: 7-27.
13. Pawlotsky JM, Roudot-Thoraval F, Bastie A et al. Factors affecting treatment responses to interferon-α in chronic hepatitis. J Infect Dis 1996; 174: 1-7.
14. Toyoda H, Kumada T, Nakano S et al. Quasispecies nature of hepatitis C virus and response to alpha interferon : significance as a predictor of direct response to interferon. J Hepatol 1997; 26: 6-13.
15. Poignet JL, Degos F, Bouchardeau F, Chauveau P, Couroucé AM. Complete response to interferon-alpha for acute hepatitis C after needlestick injury in a demodialysis nurse. J Hepatol 1995; 23: 740-1.
16. Joliot E, Vanlemmens C, Kerleau M et al. Analyse coût-efficacité du traitement de l'hépatite chronique C. Gastroenterol Clin Biol 1996; 20: 958-67.
17. Farci P, Mandas A, Ciana A et al. Treatment of chronic hepatitis D with interferon alpha-2a. N Engl J Med 1994; 330: 88-94.
18. Périgaud C, Gosselin G, Imbach JL. Potentialités et applications thérapeutiques d'analogues de nucléosides. Ann Inst Pasteur 1992; 3: 179-215.
19. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurent infection after orthopic transplantation. Lancet 1997; 349: 20-2.
20. Dusheiko GM, Main J, Thomas H at al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebocontrolled study. J Hepatol 1996; 25: 591-8.
21. Nakazono K, Ito Y, Wu C, Wu G. Inhibition of hepatitis B virus replication by targeted pretreatment of comlexed antisense DNA in vitro. Hepatology 1996; 23: 1297-303.
22. Pol S, Driss F, Carnot F, Michel ML, Berthelot P, Bréchot C. Efficacité d'une immunothérapie par vaccination contre le virus de l'hépatite B sur la multiplication virale. CR Acad Sci Paris, Life Sciences 1993; 316: 688-91.
23. Clarke BE. Approaches to the development of novel inhibitors of hepatitis C virus replication. J Vir Hep 1995; 2: 1-8.
24. Kim JL, Morgenstern KA, Lin C et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4 cofactor peptide. Cell 1996; 87: 343-5.
25. Dubois F, Desenclos JC, Mariotte N, Goudeau A. Hepatitis C in a French population base survey, 1994: seroprealence, frequency of viremia, genotype distribution and risk factors. Hepatology (sous presse).
26. Serfaty L. Résultats du traitement de l'hépatite C par interféron seul ou en association à d'autres médicaments. Gastroentérol Clin Biol (sous presse).